Research Article
The Impact of Chronic Kidney Disease and Short-Term Treatment with Rosiglitazone on Plasma Cell-Free DNA Levels
Table 1
Baseline characteristics of the study population by CKD stage.
| | | CKD stage | | | 2 | 3 | 4 | 5 | | | Median (SD) | Median (SD) | Median (SD) | Median (SD) |
| | cfDNA (ng/mL) |
8.4 (2.80) | 7.9 (3.87) | 6.8 (3.05) | 7.7 (4.86) | | hsCRP (mg/L) | 1.28 (2.38) | 1.79 (2.25) | 1.58 (1.85) | 1.14 (1.66) | | vWF (%) | 126 (26.5) | 135 (35.6) | 138.5 (27.9) | 129 (22.4) | | IL-1 (pg/mL) | 0.21 (2.3) | 0.15 (0.78) | 0.16 (0.79) | 0.17 (0.55) | | IL-6 (pg/mL) | 1.57 (3.8) | 1.3 (5.2) | 1.7 (2.2) | 1.52 (3.7) | | IL-8 (pg/mL) | 2.16 (3.7) | 2.66 (5.1) | 2.94 (4.3) | 2.91 (6.01) | | TNF (pg/mL) | 2.30 (11.3) | 5.40 (8.5) | 4.66 (9.64) | 5.40 (11.7) |
|
|
